0
German biotechnology firm CureVac does not rule out a speedy approval process for its prospective vaccine against Covid-19, its chief executive was quoted as saying, according to Reuters.
The company said on Friday that it expects to put its vaccine on the market by mid-2021. Obtaining speedy approval suggests the company is pushing for an earlier release date although CEO Franz-Werner Haas did not give any details on how likely this was.
“We are not ruling out accelerated approval, but this can only be achieved in close cooperation with the authorities,” Haas told the Boerse Online financial website.
